Pins matching place:Cambridge

Alan Turing submits "On Computable Numbers, with an Application to the Entscheidungsproblem" to the London Mathematical Society. It defines the abstract machine that became the model for every computer built since, and proves the Entscheidungsproblem undecidable.

Nature carries Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid, the paper in which Francis Crick and James Watson describe the double helix. It runs to two pages and settles how genetic instructions are held and passed on.

Georges Köhler and César Milstein report in Nature that fusing an antibody-producing cell with a myeloma cell yields a line that secretes a single antibody indefinitely. Monoclonal antibodies become the basis of the modern biologics industry.

Looking Glass Studios' Thief: The Dark Project was released for Windows in North America on 1 December 1998 (UK 4 December), published by Eidos Interactive.

Looking Glass Studios' Thief II: The Metal Age was released for Windows in North America on 23 March 2000 (Europe 31 March), published by Eidos Interactive.

On 8 February 2022 NVIDIA and SoftBank Group announced they had ended NVIDIA's planned purchase of Arm Limited because of significant regulatory challenges, and SoftBank said it would prepare an Arm public offering.

Great River Energy and Form Energy are building a 1.5 MW grid-connected storage system that can deliver rated output for 100 hours, at GRE's Cambridge peaking plant. Operation was expected by the end of 2025.

On 24 March 2026 Arm announced the Arm AGI CPU, an Arm-designed data-centre processor for agentic AI developed with Meta, marking its first production silicon product after more than 35 years of licensing designs.

On 6 May 2026 Arm reported fourth-quarter revenue of US$1.49 billion and full-year fiscal 2026 revenue of US$4.92 billion, its third straight year of more than 20% growth, and said demand for the AGI CPU already exceeded US$2 billion.

On 29 July 2026 Arm reported first-quarter fiscal 2027 revenue of US$1.29 billion, up 22% year over year, with data centre royalties more than doubling and AGI CPU demand still above US$2 billion.

Governor Healey broke ground on the $1.3 billion replacement of Draw One, the 1931 drawbridge carrying every northside Commuter Rail line and the Amtrak Downeaster into North Station, which will grow from four tracks to six.

Using South Africa's MeerKAT array, a Harvard & Smithsonian team reports the first direct detection of auroral radio emission from a planet outside the Solar System, implying a magnetic field of at least 1,250 gauss on the giant planet Beta Pictoris b.

A year after its $9.1 billion takeover, Sanofi is laying off 229 former Blueprint Medicines staff and closing Blueprint's two Sidney Street offices in Cambridge, with separations from 9 October 2026 to late June 2027.

The world's largest three-day rowing event returns to the Charles River between Boston and Cambridge on 16-18 October 2026, with nearly 12,000 athletes and more than 370,000 spectators expected. Crews race a head course of about three miles against the clock, starting roughly fifteen seconds apart.

The world's largest two-day rowing regatta sends thousands of crews down the Charles River. Spectators watch from bridges and the river banks in Boston and Cambridge.

Auberge Collection's first London hotel, Cambridge House at 94 Piccadilly, is preparing for a February 2027 opening with 102 rooms, 24 of them suites, in the Grade I-listed former In & Out club. Jean-Louis Deniot designed the hotel and Major Food Group runs the restaurant.

AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Kalshi’s recession market for 2027 prices the chance of two consecutive quarters of negative GDP growth between Q4 2026 and Q4 2027, on the Bureau of Economic Analysis’s advance estimates — despite the KXRECSSNBER ticker, no NBER call is involved. On 20 September 2026 it sat at 25%, its 2026 contract at 6%, and Polymarket’s cumulative "recession by end of 2027" book, which also counts an NBER announcement, was higher still at 34.5%.

The first of two connected towers in Mass General's Cambridge Street expansion takes its first patients, bringing 450 beds and 12 levels of operating, procedural and interventional space for the Corrigan Minehan Heart Center and the Mass General Cancer Center. Turner topped out the steel in February 2025; the second tower is not due until 2030.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

The $1.3 billion replacement of North Station's Draw One drawbridge is due to finish in fall 2032, adding two tracks over the Charles River and two station tracks for the northside Commuter Rail and the Amtrak Downeaster.